Description

Erbisol vials 2 ml, #10

Active Ingredients:

1 ml of the medication contains a complex of natural non-protein low-molecular organic compounds of non-hormonal origin, derived from animal embryonic tissue, containing oligopeptides and glycopeptides (total 0.07 – 1.0 mg), nucleotides, and amino acids.

Inactive Ingredient:

0.9% isotonic sodium chloride solution.

Erbisol Pharmaceutical Dosage Form:

Solution for injections.

Main Physical and Chemical Properties:

Clear or slightly opalescent colorless or light yellow solution with a specific odor.

Pharmacological Properties:

Erbisol belongs to the group of medications stimulating immunity and providing a positive effect on the functioning of the gastrointestinal tract, particularly the liver.

Erbisol is a combination of natural elements with low molecular weight and does not belong to hormonal medications. These components are obtained from the tissue of calf embryos. It contains various elements related to oligopeptides, glycopeptides, nucleotides, and amino acids.

It is an adaptogen contributing to the harmonization of the unbalanced immune system, providing a positive effect on the dynamics of recovery in case of several diseases of the body.

In particular, it improves the condition of the liver, lungs, pancreas, and other organs during diseases, increasing the body’s resistance. As a result, the severity of the clinical symptoms of the disease is weakened, and there is an active increase in positive dynamics. Speaking about respiratory system diseases, breathing is facilitated, and the necessity to use inhalers and bronchodilators is reduced.

Healing of ulcers of the stomach and duodenum is accelerated, and the processes of liver tissue regeneration are activated. In oncology, the need for chemotherapy or radiotherapy can be reduced.

Sports Medicine:

If you want to normalize the adaptive capabilities of sportsmen, use the pulsating course of immunomodulation, hepatoprotection, repair, and adaptation with Erbisol.

Rules for Taking the Medication in Sports Medicine:

Cycle: 30 days, 50 ampoules according to the scheme:

From 1 to 3 days: 1 time (in the evening), from 4 to 8 days: 2 times (in the morning and in the evening), from 9 to 10 days: 1 time (in the evening), from 11 to 15 days: 2 times (in the morning and in the evening), from 16 to 17 day: 1 time (in the evening), from 18 to 22 day: 2 times (in the morning and in the evening), from 23 to 24 day: 1 time (in the evening), from 25 to 29 day: 2 times (in the morning and in the evening), on 30 day: 1 time in the evening.

It is advisable to inject medications on an empty stomach 1-2 hours before meals or 2-3 hours after meals. Tea, juices, water, etc. can be consumed at any time. Note: 1 (one) ampoule of 2 ml of ERBISOL® intramuscularly.

Overdosage:

Overdosage can cause short-term hyperexcitability, which does not require special treatment.

Side Effects:

Usually, this medication is well tolerated without causing complications.

The use of the medication during the first 2-5 days can cause a short-term exacerbation of the current chronic disease.

In theory, the use of this medication can occasionally cause allergic side reactions, in particular:

• Allergic urticaria, itching, rash;
• Hyperemia.

Storage Terms and Conditions:

Expiration date is 5 years from the date of manufacture specified on the package.

The storage temperature is from 5°C to 12°C.

---

An evaluation of the efficacy of the new Ukrainian preparation Erbisol in patients with chronic hepatitis